Aurobindo Pharma (AUROPHARMA.NS) Stock Price

Aurobindo Pharma Price

NSE·CLOSED
1,658.00INR+69.10 (+4.26 %)
Market closed

Revenue has compounded at 17.0% per year over the past 19 years to 317.24 B INR. Earnings per share have grown at 22.6% per year over the last 19 years. Aurobindo Pharma's net margin stands at 11.0%, down from 21.5% several years earlier. Aurobindo Pharma currently offers a dividend yield of about 0.24%. The payout ratio is around 7% of earnings. The dividend has grown at 5.3% per year over the past 19 years. Analysts set a median price target of 1,407.60 INR, implying 15.1% below the current price. Of 31 analysts, 25 rate the stock a buy — an overall Buy consensus. The stock trades about 62% above its 52-week low.

Aurobindo Pharma stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Aurobindo Pharma over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Aurobindo Pharma stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Aurobindo Pharma's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Aurobindo Pharma Stock Price History
DateAurobindo Pharma Price
8/7/20261,658.00 INR
8/6/20261,588.90 INR
8/5/20261,613.40 INR
8/4/20261,553.00 INR
7/31/20261,580.20 INR
7/30/20261,600.00 INR
7/28/20261,548.10 INR
7/27/20261,549.40 INR
7/24/20261,532.00 INR
7/23/20261,524.90 INR
7/22/20261,533.60 INR
7/21/20261,579.70 INR
7/20/20261,559.60 INR
7/17/20261,535.80 INR
7/15/20261,550.20 INR
7/14/20261,552.80 INR
7/13/20261,549.30 INR
7/10/20261,564.70 INR
7/9/20261,587.40 INR
7/8/20261,557.40 INR
7/7/20261,583.10 INR
7/6/20261,594.60 INR
7/3/20261,620.00 INR
7/2/20261,561.00 INR
7/1/20261,552.60 INR
6/30/20261,578.70 INR
6/29/20261,547.50 INR
6/25/20261,555.20 INR
6/24/20261,530.60 INR
6/23/20261,534.20 INR
6/22/20261,491.90 INR
6/19/20261,497.80 INR
6/18/20261,443.70 INR
6/17/20261,422.40 INR
6/16/20261,396.70 INR
6/15/20261,436.80 INR
6/12/20261,472.80 INR
6/11/20261,464.10 INR
6/10/20261,455.00 INR
6/9/20261,449.00 INR
6/8/20261,451.80 INR
6/5/20261,462.30 INR
6/4/20261,463.60 INR
6/3/20261,440.40 INR
6/2/20261,429.20 INR
6/1/20261,433.70 INR
5/29/20261,426.40 INR
5/27/20261,435.90 INR
5/26/20261,461.20 INR
5/25/20261,454.60 INR
5/22/20261,463.50 INR
5/21/20261,546.70 INR
5/20/20261,536.50 INR
5/19/20261,512.80 INR
5/18/20261,500.50 INR
5/15/20261,511.80 INR
5/14/20261,510.90 INR
5/13/20261,497.50 INR
5/12/20261,488.20 INR
5/11/20261,486.60 INR
5/8/20261,487.30 INR
5/7/20261,478.70 INR
5/6/20261,484.00 INR
5/5/20261,428.10 INR
5/4/20261,376.00 INR
5/1/20261,389.50 INR
4/30/20261,389.50 INR
4/29/20261,396.80 INR
4/28/20261,422.60 INR
4/27/20261,416.70 INR
4/24/20261,413.80 INR
4/23/20261,435.40 INR
4/22/20261,421.20 INR
4/21/20261,391.70 INR
4/20/20261,367.80 INR
4/17/20261,386.00 INR
4/16/20261,386.50 INR
4/15/20261,373.90 INR
4/13/20261,339.80 INR
4/10/20261,349.40 INR
4/9/20261,340.40 INR
4/8/20261,335.70 INR
4/7/20261,330.00 INR
4/6/20261,340.40 INR
4/2/20261,333.70 INR
4/1/20261,342.10 INR
3/30/20261,304.40 INR
3/27/20261,314.20 INR
3/25/20261,310.00 INR
3/24/20261,279.80 INR
3/23/20261,284.00 INR
3/20/20261,292.00 INR
3/19/20261,253.00 INR
3/18/20261,268.00 INR
3/17/20261,289.80 INR
3/16/20261,271.50 INR
3/13/20261,299.30 INR
3/12/20261,310.20 INR
3/11/20261,302.90 INR
3/10/20261,283.10 INR
3/9/20261,248.00 INR
3/6/20261,232.00 INR
3/5/20261,225.50 INR
2/26/20261,221.70 INR
2/25/20261,215.20 INR
2/24/20261,164.40 INR
2/23/20261,148.70 INR
2/20/20261,157.10 INR
2/19/20261,172.00 INR
2/18/20261,168.60 INR
2/17/20261,181.00 INR
2/16/20261,184.60 INR
2/13/20261,145.60 INR
2/12/20261,157.60 INR
2/11/20261,142.00 INR
2/10/20261,124.10 INR
2/9/20261,204.00 INR
2/6/20261,195.00 INR
2/5/20261,176.90 INR
2/4/20261,212.70 INR
2/3/20261,226.10 INR
2/2/20261,171.00 INR
2/1/20261,164.80 INR
1/30/20261,207.70 INR
1/29/20261,150.60 INR
1/28/20261,142.60 INR
1/27/20261,133.10 INR
1/23/20261,132.50 INR
1/22/20261,145.30 INR
1/21/20261,121.70 INR
1/20/20261,141.70 INR
1/19/20261,164.10 INR
1/16/20261,166.30 INR
1/14/20261,180.00 INR
1/13/20261,161.40 INR
1/12/20261,169.90 INR
1/9/20261,195.00 INR
1/8/20261,210.00 INR
1/7/20261,235.40 INR
1/6/20261,231.30 INR
1/5/20261,207.40 INR
1/2/20261,215.40 INR
1/1/20261,193.00 INR
12/31/20251,183.00 INR
12/30/20251,186.30 INR
12/29/20251,199.40 INR
12/26/20251,208.30 INR
12/24/20251,211.40 INR
12/23/20251,216.60 INR
12/22/20251,224.00 INR
12/19/20251,225.10 INR
12/18/20251,209.30 INR
12/17/20251,192.00 INR
12/16/20251,178.10 INR
12/15/20251,186.30 INR
12/12/20251,195.10 INR
12/11/20251,174.80 INR
12/10/20251,169.30 INR
12/9/20251,163.60 INR
12/8/20251,177.40 INR
12/5/20251,217.90 INR
12/4/20251,223.10 INR
12/3/20251,208.90 INR
12/2/20251,214.00 INR
12/1/20251,216.20 INR
11/28/20251,226.70 INR
11/27/20251,235.80 INR
11/26/20251,227.40 INR
11/25/20251,205.90 INR
11/24/20251,195.20 INR
11/21/20251,203.40 INR
11/20/20251,210.00 INR
11/19/20251,232.70 INR
11/18/20251,236.90 INR
11/17/20251,236.90 INR
11/14/20251,222.50 INR
11/13/20251,209.10 INR
11/12/20251,190.30 INR
11/11/20251,168.20 INR
11/10/20251,154.80 INR
11/7/20251,123.80 INR
11/6/20251,140.60 INR
11/4/20251,149.10 INR
11/3/20251,156.10 INR
10/31/20251,144.00 INR
10/30/20251,102.50 INR
10/29/20251,111.70 INR
10/28/20251,099.40 INR
10/27/20251,093.00 INR
10/24/20251,090.90 INR
10/23/20251,099.10 INR
10/21/20251,099.00 INR
10/20/20251,101.00 INR
10/17/20251,100.20 INR
10/16/20251,106.30 INR
10/15/20251,109.00 INR
10/14/20251,124.80 INR
10/13/20251,136.80 INR
10/10/20251,130.10 INR
10/9/20251,118.90 INR
10/8/20251,070.80 INR
10/7/20251,091.50 INR
10/6/20251,096.50 INR
10/3/20251,095.00 INR
10/1/20251,086.00 INR
9/30/20251,085.00 INR
9/29/20251,089.50 INR
9/26/20251,090.00 INR
9/25/20251,097.00 INR
9/24/20251,094.00 INR
9/23/20251,105.40 INR
9/22/20251,117.40 INR
9/19/20251,120.40 INR
9/18/20251,131.00 INR
9/17/20251,095.30 INR
9/16/20251,090.00 INR
9/15/20251,100.00 INR
9/12/20251,094.40 INR
9/11/20251,109.20 INR
9/10/20251,050.10 INR
9/9/20251,043.90 INR
9/8/20251,041.90 INR
9/5/20251,048.00 INR
9/4/20251,036.80 INR
9/3/20251,034.90 INR
9/2/20251,022.20 INR
9/1/20251,025.00 INR
8/29/20251,027.90 INR
8/28/20251,026.30 INR
8/26/20251,047.00 INR
8/25/20251,067.00 INR
8/22/20251,050.40 INR
8/21/20251,041.00 INR
8/20/20251,046.10 INR
8/19/20251,089.70 INR
8/18/20251,090.00 INR
8/14/20251,083.60 INR
8/13/20251,078.20 INR
8/12/20251,058.20 INR
Access this data via the Eulerpool API
Get Free API Key

Aurobindo Pharma Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
248.55 B INR
25.38 B INR
19.28 B INR
Jan 1, 2024
290.02 B INR
43.85 B INR
31.73 B INR
Jan 1, 2025
317.24 B INR
49.83 B INR
34.86 B INR
Jan 1, 2026 (e)
334.73 B INR
70.60 B INR
35.91 B INR
Jan 1, 2027 (e)
394.68 B INR
83.25 B INR
45.12 B INR
Jan 1, 2028 (e)
437.49 B INR
92.28 B INR
51.70 B INR
Jan 1, 2029 (e)
472.79 B INR
99.73 B INR
57.92 B INR
Jan 1, 2030 (e)
233.61 M INR
0.00 INR
0.00 INR

Aurobindo Pharma Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 11, 2026, 2:51 PM
 
REVENUEB INR
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB INR
EBITB INR
EBIT MARGIN%
NET INCOMEB INR
NET INCOME GROWTH%
DIV.INR
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
139.55150.90165.00195.64230.99247.75234.56248.55290.02317.24334.73394.68437.49472.790.230.32
15.148.139.3418.5718.077.26-5.325.9716.689.385.5117.9110.858.07-99.9536.05
50.0951.7354.9551.1954.0656.3952.8750.4152.9054.8754.8754.8754.8754.8754.8754.87
69.9078.0690.67100.14124.87139.69124.02125.30153.42174.08183.67216.57240.06259.430.130.17
28.0130.2032.4733.0439.3544.1933.0025.3843.8549.8370.6083.2592.2899.73––
20.0720.0119.6816.8917.0317.8414.0710.2115.1215.7121.0921.0921.0921.09––
20.2523.0224.2323.6528.4553.3526.4819.2831.7334.8635.9145.1251.7057.92––
28.5113.665.28-2.4120.3287.51-50.36-27.2164.619.863.0225.6414.5912.03––
2.653.902.252.504.255.336.0015.009.004.0016.0019.2023.04–––
-35.3747.17-42.3111.1170.0025.4112.57150.00-40.00-55.56300.0020.0020.00–––
584.00585.00586.00586.00586.00586.00586.00585.94585.94582.87582.87582.87582.87582.87582.87582.87
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Aurobindo Pharma generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Aurobindo Pharma retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Aurobindo Pharma's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Aurobindo Pharma has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Aurobindo Pharma's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Aurobindo Pharma stock margins

The Aurobindo Pharma margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Aurobindo Pharma. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Aurobindo Pharma.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
56.39 %
17.84 %
21.53 %
Jan 1, 2022
52.87 %
14.07 %
11.29 %
Jan 1, 2023
50.41 %
10.21 %
7.75 %
Jan 1, 2024
52.90 %
15.12 %
10.94 %
Jan 1, 2025
54.87 %
15.71 %
10.99 %
Jan 1, 2026 (e)
54.87 %
21.09 %
10.73 %
Jan 1, 2027 (e)
54.87 %
21.09 %
11.43 %
Jan 1, 2028 (e)
54.87 %
21.09 %
11.82 %

Aurobindo Pharma Stock Revenue, EBIT, Earnings per Share

The Aurobindo Pharma earnings per share therefore indicates how much revenue Aurobindo Pharma has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
422.77 INR
75.41 INR
91.04 INR
Jan 1, 2022
400.26 INR
56.32 INR
45.19 INR
Jan 1, 2023
424.20 INR
43.31 INR
32.90 INR
Jan 1, 2024
494.96 INR
74.83 INR
54.15 INR
Jan 1, 2025
544.27 INR
85.49 INR
59.81 INR
Jan 1, 2026 (e)
574.28 INR
121.13 INR
61.61 INR
Jan 1, 2027 (e)
677.12 INR
142.82 INR
77.41 INR
Jan 1, 2028 (e)
750.58 INR
158.32 INR
88.71 INR

Aurobindo Pharma business model & stock analysis

Aurobindo Pharma Ltd is a global pharmaceutical company based in India. It was founded in 1986 by P.V. Ramprasad Reddy, K. Nityananda Reddy, and Kambhampati Hari Babu. It has become one of the leading companies in the industry over the past 35 years. The company's business model is based on the production and distribution of generics, active pharmaceutical ingredients, and biosimilars. It operates in several divisions, covering a wide range of products. Aurobindo Pharma's main division is the manufacturing of generics, including both simple generics and complex products like biosimilars. The company also produces a variety of pharmaceutical ingredients used in industries such as pharmacy, cosmetics, and food. In addition, Aurobindo is involved in the production of biosimilars, which are biological drugs that have similar properties to existing biological products. These products have the potential to improve access to life-saving medications and generate significant cost savings. Aurobindo also manufactures products for the veterinary medicine industry, including antibiotics, antiparasitics, and vitamins. The company has also established a strong presence in the American market in recent years through acquisitions and offers a wide range of products. It has also expanded its presence in Europe, Asia, and Africa. In 2020, Aurobindo Pharma played a significant role in combating the COVID-19 pandemic by introducing several medications that can be used to treat the virus, such as hydroxychloroquine and azithromycin for mild to moderate cases. The company has earned a reputation as a leader in the generics and active pharmaceutical ingredient markets and aims to provide high-quality medications at affordable prices, making a positive contribution to global health improvement.

Aurobindo Pharma SWOT Analysis

Strengths

1. Strong market position: Aurobindo Pharma Ltd has achieved a solid market position in the pharmaceutical industry.

2. Diversified product portfolio: The company offers a wide range of products in various therapeutic segments, which helps reduce dependence on a single product category.

3. Robust manufacturing capabilities: Aurobindo Pharma has established efficient manufacturing facilities, allowing for cost-effective production and timely delivery of products.

4. Extensive global presence: The company has a widespread international footprint, operating across multiple geographies, which helps in revenue diversification and potential growth opportunities.

Weaknesses

1. Quality control challenges: Aurobindo Pharma has faced certain quality control issues in the past, which have impacted its brand reputation and may lead to regulatory scrutiny.

2. Overdependence on few key markets: The company heavily relies on a small number of markets for a significant portion of its revenue, making it vulnerable to market-specific risks.

3. Limited pipeline of novel drugs: Aurobindo Pharma's focus has been primarily on generic drugs, lacking a substantial pipeline of breakthrough innovative medicines for future growth.

Opportunities

1. Increasing generic drug demand: The growing preference for generic medications presents an opportunity for Aurobindo Pharma to expand its market share and revenue.

2. Expansion into emerging markets: The company can explore untapped markets in developing countries, where there is a rising need for affordable healthcare solutions.

3. Strategic partnerships and acquisitions: Aurobindo Pharma can pursue collaborations or acquisitions to access new technologies, strengthen its product portfolio, or enter new markets.

Threats

1. Intense competition: The pharmaceutical industry is highly competitive, with numerous players vying for market share, which could lead to pricing pressures and reduced profitability.

2. Stringent regulatory requirements: Compliance with stringent regulations in various countries can pose challenges and increase costs for Aurobindo Pharma.

3. Intellectual property rights issues: The company may face legal disputes or delays in product launches due to patent infringement allegations or licensing complications.

Aurobindo Pharma Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Aurobindo Pharma historical P/E ratio, EBIT multiple, and P/S ratio

Aurobindo Pharma annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Aurobindo Pharma shares outstanding

The number of shares of Aurobindo Pharma was 582.87 M in 2025. This indicates how many shares Aurobindo Pharma is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
586.00 M Stocks
Jan 1, 2022
586.00 M Stocks
Jan 1, 2023
585.94 M Stocks
Jan 1, 2024
585.94 M Stocks
Jan 1, 2025
582.87 M Stocks
Jan 1, 2026 (e)
582.87 M Stocks
Jan 1, 2027 (e)
582.87 M Stocks
Jan 1, 2028 (e)
582.87 M Stocks

Aurobindo Pharma stock splits

In Aurobindo Pharma's history, there have been no stock splits.

Aurobindo Pharma Dividend History

31 years of dividend payments

YearAnnual DividendYoY ChangePayments
20254.00INR↑ 166.7%1×
Aug 8, 20254.00INR↑ 166.7%1/1
20241.50INR↓ 75.0%1×
20236.00INR 0.0%2×
20226.00INR↑ 33.3%2×
20214.50INR↑ 5.9%3×
20204.25INR↑ 70.0%3×
20192.50INR↑ 11.1%2×
20182.25INR↓ 18.2%2×
20172.75INR↑ 3.8%2×
20162.65INR↓ 35.4%3×

Aurobindo Pharma dividend history and estimates

In 2025, Aurobindo Pharma paid a dividend amounting to 4.00 INR. Dividend means that Aurobindo Pharma distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021 (e)
4.50 INR
0.83 INR
Jan 1, 2022 (e)
6.00 INR
0.00 INR
Jan 1, 2023 (e)
6.00 INR
9.00 INR
Jan 1, 2024 (e)
1.50 INR
7.50 INR
Jan 1, 2025 (e)
0.00 INR
4.00 INR
Jan 1, 2026 (e)
4.00 INR
12.00 INR
Jan 1, 2027 (e)
0.00 INR
19.20 INR
Jan 1, 2028 (e)
0.00 INR
23.04 INR

Aurobindo Pharma dividend payout ratio

In 2025, Aurobindo Pharma had a payout ratio of 6.69%. The payout ratio indicates the percentage of the company's profits that Aurobindo Pharma distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
4.94 %
Jan 1, 2022
13.27 %
Jan 1, 2023
18.24 %
Jan 1, 2024
2.77 %
Jan 1, 2025
6.69 %
Jan 1, 2026 (e)
25.97 %
Jan 1, 2027 (e)
24.80 %
Jan 1, 2028 (e)
25.97 %

Current Aurobindo Pharma forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
1.85 %
Buy
80.65 % (25)
Hold
3.23 % (1)
Sell
16.13 % (5)
12M Price Target
1,407.60
Last Price
1,648.00
Currency
INR
12M Return Potential
-14.59 %
LTM Return
0 %

Aurobindo Pharma Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/25/202416.10INR-75.02 BINR-2024 Q4
2/7/202416.16INR-74.25 BINR-2024 Q3

EESG©

Eulerpool ESG Scorecard© for the Aurobindo Pharma stock

58/100
58
Environment
73
Social
42
Governance
E

Environment

20
Scope 1 - Direct Emissions414,356
Scope 2 - Indirect emissions from purchased energy553,115
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions967,471
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees13
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Aurobindo Pharma shareholder structure

% Name
33.37986%
RPR Sons Advisors Pvt. Ltd.
RPR Sons Advisors Pvt. Ltd.
4.35081%
Reddy (Nityananda K)
Reddy (Nityananda K)
4.28256%
Quant Money Managers Ltd
Quant Money Managers Ltd
3.44208%
Kambam (Kirthi Reddy)
Kambam (Kirthi Reddy)
3.24199%
HDFC Asset Management Co., Ltd.
HDFC Asset Management Co., Ltd.
3.05962%
Reddy (Ramaprasad P V)
Reddy (Ramaprasad P V)
...

Aurobindo Pharma Beneficial Ownership Filings (SEC 13D/G)

Free Float
48.0%
Float Shares
-
Shares Outstanding
-

Aurobindo Pharma Executives and Management Board

12 members · avg. age 58 · 17 % women

KR

Mr. Kambam Reddy (67)

Executive Vice Chairman of the Board, Managing Director, Promoter · since 2022

54.69 M INR

Management

SS

Mr. Santhanam Subramanian

Chief Financial Officer

48.60 M INR
BR

Mr. B. Adi Reddy

Compliance Officer, Company Secretary · since 2024

8.97 M INR

Board of Directors

MR

Mr. Mettu Madan Reddy (65)

Whole-Time Director · since 2006

69.79 M INR
SK

Shri. Mangalam Kumar (64)

Non-Executive Independent Chairman of the Board

2.00 M INR
DJ

Dr. Deepali Joshi (65)

Non-Executive Independent Director

2.00 M INR
SM

Mr. Santanu Mukerjee

Non-Executive Independent Director

2.00 M INR
GV

Mr. Girish Vanvari (53)

Non-Executive Independent Director

2.00 M INR
PR

Mr. Penaka Sarath Reddy (40)

Non-Executive Non-Independent Director · since 2007

900,000.00 INR

Frequently asked questions about Aurobindo Pharma

Aurobindo Pharma Ltd is a pharmaceutical company that operates under a vertically integrated business model. The company is engaged in the development, manufacturing, and marketing of generic pharmaceuticals and active pharmaceutical ingredients (APIs) globally. With a strong focus on research and development, Aurobindo Pharma strives to provide affordable and high-quality healthcare products to patients worldwide. The company's diverse product portfolio spans multiple therapeutic areas, including antiretrovirals, antibiotics, cardiovasculars, and more. Aurobindo Pharma's commitment to innovation, quality, and accessibility has catapulted it to become one of the leading players in the generic pharmaceutical industry.

Aurobindo Pharma Ltd primarily operates in the pharmaceutical industry.

Some of the main competitors of Aurobindo Pharma Ltd in the market include Teva Pharmaceutical Industries Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Dr. Reddy's Laboratories Ltd.

Aurobindo Pharma Ltd is a leading pharmaceutical company with a rich history and background. Established in 1986, the company has rapidly grown to become one of the largest vertically integrated generic pharmaceutical companies globally. Headquartered in Hyderabad, India, Aurobindo Pharma is committed to delivering high-quality, affordable medicines across various therapeutic areas. With a strong focus on research and development, the company has a diverse portfolio of over 400 products approved by regulatory authorities in more than 150 countries. Aurobindo Pharma's consistent growth and dedication to healthcare have earned it a strong reputation in the pharmaceutical industry.

Aurobindo Pharma Ltd has accomplished several significant milestones in its journey. By adhering to high-quality standards and manufacturing innovative pharmaceutical products, the company has gained recognition worldwide. Aurobindo Pharma Ltd has achieved notable milestones such as receiving the US FDA approval for multiple abbreviated new drug applications (ANDAs), expanding its global footprint through strategic acquisitions, and consistently delivering strong financial performance. With a focus on research and development, Aurobindo Pharma Ltd continues to enhance its product portfolio and bring affordable healthcare solutions to patients across the globe.

Aurobindo Pharma Ltd is primarily present in various countries and regions across the globe. The company has a strong global footprint and operates in over 150 countries, including key markets such as the United States, Europe, India, and several other emerging markets. Aurobindo Pharma Ltd has established a significant presence in these regions, leveraging its robust manufacturing capabilities, research and development expertise, and a wide range of high-quality generic pharmaceutical products. The company's extensive international presence enables it to cater to a diverse customer base and contribute to improving healthcare access worldwide.

Aurobindo Pharma Ltd represents values of excellence, integrity, and innovation. The company's corporate philosophy revolves around delivering high-quality and affordable pharmaceutical products to improve global healthcare. Aurobindo Pharma is committed to maintaining the highest standards of regulatory compliance and ensuring patient safety. With a focus on research and development, the company strives to create and provide access to a diverse range of medicines across various therapeutic areas. Aurobindo Pharma's mission is to enhance the well-being and quality of life for individuals worldwide by consistently delivering superior value to its stakeholders in an ethical and sustainable manner.

Analysts currently set an average price target of 1,374.72 INR for the Aurobindo Pharma stock (median: 1,407.60 INR), implying -16.6 % versus the latest price. The consensus is based on 31 analyst ratings.

Aurobindo Pharma Analyst Price Targets 2026

32 analysts currently rate the Aurobindo Pharma stock: 26 recommend buying, 1 holding and 5 selling. For 2026, analysts expect Aurobindo Pharma to generate revenue of 334.73 B INR and earnings per share of 61.61 INR.

Aurobindo Pharma Analyst Price Targets 2026

Converted at the current exchange rate, the Aurobindo Pharma share trades at 15.06 EUR (1,658.00 INR).

Aurobindo Pharma Ltd is a leading global pharmaceutical manufacturer with a wide portfolio of pharmaceuticals and active pharmaceutical ingredients (APIs). The company is headquartered in India and operates 18 production facilities in 7 countries worldwide to serve a variety of therapy areas such as oncology, neurology, anti-infectives, and cardiology. Aurobindo Pharma Ltd has a well-diversified business with various segments focusing on the manufacturing and marketing of pharmaceutical formulations and APIs for the domestic and international markets. The focus is on developing high-quality and cost-effective products to meet the needs of patients worldwide. One of the key segments of Aurobindo Pharma Ltd is generic manufacturing. The company produces a variety of generics for use in various therapy areas such as pain relief, diabetes, cardiovascular diseases, and infectious diseases. Additionally, the company also offers customized development services for companies in need of new formulations and APIs. Another important segment of Aurobindo Pharma Ltd is API production. The company produces a wide range of APIs used in the manufacturing of generics and finished pharmaceuticals. The focus is on manufacturing products of the highest quality at a competitive price. Aurobindo Pharma Ltd is also a leading provider of in vitro diagnostics and diabetology products. The company also offers biological products and biosimilars. Aurobindo Pharma Ltd strives to bring innovative biological drugs to the market that contribute to improving health and quality of life. The focus is on developing biosimilars that are cost-effective while meeting the highest standards of quality and safety. The company also has a presence in the field of new molecule development. Aurobindo Pharma Ltd, as well as its subsidiaries Agila Specialties and Oncobiologics, focus on the development and marketing of proprietary products that contribute to patient care improvement. In summary, Aurobindo Pharma Ltd has broad business activities, including the manufacturing and marketing of pharmaceutical formulations, APIs, and biological products. The company's focus is on offering cost-effective, high-quality products to enhance healthcare worldwide. Aurobindo Pharma Ltd is a leading provider of generics and also offers customized development and production services. The company will continue to invest in the development of new molecules to further diversify its portfolio.

The expected revenue of Aurobindo Pharma is 334.73 B INR. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Aurobindo Pharma is 35.91 B INR. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Aurobindo Pharma is currently 26.91. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Aurobindo Pharma stock.

The price-to-sales ratio (P/S) of Aurobindo Pharma is currently 2.89. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Aurobindo Pharma stock.

The Eulerpool Quality Score for Aurobindo Pharma is 8/10.

The ISIN of Aurobindo Pharma is INE406A01037. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Aurobindo Pharma is AUROPHARMA.NS. The ticker symbol is used to trade Aurobindo Pharma shares on the stock exchange.

Over the past 12 months, Aurobindo Pharma paid a dividend of 4.00 INR . This corresponds to a dividend yield of about 0.24 %. For the coming 12 months, Aurobindo Pharma is expected to pay a dividend of 19.20 INR.

The current dividend yield of Aurobindo Pharma is 0.24 %.

Aurobindo Pharma pays a dividend, distributed in the months of , , , .

Aurobindo Pharma paid dividends every year for the past 31 years.

For the upcoming 12 months, dividends amounting to 19.20 INR are expected. This corresponds to a dividend yield of 1.16 %.

Aurobindo Pharma is assigned to the 'Health' sector.

To receive the latest dividend of Aurobindo Pharma from amounting to 4 INR, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Aurobindo Pharma distributed 4.5 INR as dividends.

The dividends of Aurobindo Pharma are distributed in INR.

All fundamentals and in-depth analysis of Aurobindo Pharma

Our stock analysis for Aurobindo Pharma stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Aurobindo Pharma. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Aurobindo Pharma Stock
Aurobindo Pharma Revenue→
Aurobindo Pharma Stock
Aurobindo Pharma Net Income→
Aurobindo Pharma Stock
Aurobindo Pharma P/E→
Aurobindo Pharma Stock
Aurobindo Pharma P/S→
Aurobindo Pharma Stock
Aurobindo Pharma EBIT→
Aurobindo Pharma Stock
Aurobindo Pharma Dividend→
Aurobindo Pharma Stock
Aurobindo Pharma Directors Dealings→
Aurobindo Pharma Stock
Aurobindo Pharma Stocks→
Aurobindo Pharma Stock
Aurobindo Pharma Market capitalization→
Aurobindo Pharma Stock
Aurobindo Pharma Debt→
Aurobindo Pharma Stock
Aurobindo Pharma Liabilities→
Aurobindo Pharma Stock
Aurobindo Pharma Equity→
Aurobindo Pharma Stock
Aurobindo Pharma AAQS→
Aurobindo Pharma Stock
Aurobindo Pharma Employees→
Aurobindo Pharma Stock
Aurobindo Pharma ROE→
Aurobindo Pharma Stock
Aurobindo Pharma ROA→
Aurobindo Pharma Stock
Aurobindo Pharma ROCE→
Aurobindo Pharma Stock
Aurobindo Pharma News→
Aurobindo Pharma Stock
Aurobindo Pharma Analyst Price Targets→

Health Stocks

Aurora CannabisAuro LaboratoriesAustar LifesciencesAurisco Pharmaceutical CoAustco HealthcareAurinia PharmaceuticalsAustralian Clinical LabsAura BiosciencesAutek ChinaAunaAutobio Diagnostics CoaTyr PharmaAll Stocks A–Z →